Abbott Buys Remaining Stake In Mavik And Tarka From Aventis For $300 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott originally obtained marketing rights for the two cardiovascular drugs under a 1991 licensing agreement. Abbott expects peak sales to reach $700 mil. (versus $200 mil.-plus in 2003). The sale is not related to the Sanofi merger, Aventis says, but rather is part of an effort to divest underperforming brands.